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Impact of menopause and diabetes 
on atherogenic lipid profile: is it worth to 
analyse lipoprotein subfractions to assess 
cardiovascular risk in women?
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Abstract 
Cardiovascular disease is the leading cause of death in women at advanced age, who are affected a decade later 
compared to men. Cardiovascular risk factors in women are not properly investigated nor treated and events are 
frequently lethal. Both menopause and type 2 diabetes substantially increase cardiovascular risk in the female sex, 
promoting modifications on lipid metabolism and circulating lipoproteins. Lipoprotein subfractions suffer a shift after 
menopause towards a more atherogenic lipid profile, consisted of hypertriglyceridemia, lower levels of both total 
high density lipoprotein (HDL) and its subfraction  HDL2, but also higher levels of  HDL3 and small low-density lipopro-
tein particles. This review discusses the impact of diabetes and menopause to the lipid profile, challenges in lipopro-
tein subfractions determination and their potential contribution to the cardiovascular risk assessment in women. It is 
still unclear whether lipoprotein subfraction changes are a major driver of cardiometabolic risk and which modifica-
tions are predominant. Prospective trials with larger samples, methodological standardizations and pharmacological 
approaches are needed to clarify the role of lipoprotein subfractions determination on cardiovascular risk prediction 
and intervention planning in postmenopausal women, with or without DM.
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Background
Cardiovascular disease (CVD), particularly coronary 
artery disease (CAD) [1], is a major cause of death in 
women, who develop it about 10 years later then men [2]. 
Traditional risk factors are present at a high frequency in 
individuals with CAD but are lacking in a not negligible 
proportion. Risk calculators usually underestimate the 
real CVD risk in women and their CAD episodes are fre-
quently fatal [3–5].
Hypercholesterolemia is the major driven cause for 
CVD in both sexes [6, 7] and its treatment has been asso-
ciated with significant reductions in morbidity and mor-
tality [8–10]. Postmenopausal women tend to deteriorate 
lipid profile that becomes more atherogenic than their 
premenopausal counterpart [11, 12]. After menopause, 
total cholesterol (TC) and low-density lipoprotein cho-
lesterol (LDL-c) usually increase, and these changes are 
accompanied by a decrease in high-density lipoprotein 
cholesterol (HDL-c) and an increase in triglycerides (TG) 
[13, 14]. In addition to these major lipid abnormalities, 
also modifications in size and density of these lipoprotein 
particles are expected to happen after the loss of ovarian 
hormonal production [15–18]. This partially explains the 
increased cardiovascular risk in postmenopausal women 
[2, 19], particularly among those with an earlier onset of 
menopause [20].
Hyperglycemia contributes to the elevation of cardio-
vascular risk of populations. Increasing prevalence rates 
of type 2 diabetes mellitus (DM) have been attributed to 
aging, modern lifestyle and obesity epidemic, which pre-
disposes to several metabolic disturbances linked by the 
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insulin resistance [21–23]. In men and women with DM 
a typical dyslipidemia was described, characterized by 
hypertriglyceridemia, low levels of HDL-c and increased 
proportion of small-dense LDL particles, known to be 
more prone to oxidation [24–26]. Elevated glucose levels 
have also been associated with dysfunctional lipoprotein 
subfractions, contributing to a more atherogenic lipid 
profile in both sexes [27, 28]. Despite sharing these lipid 
abnormalities with the male sex, the diabetic woman has 
a more aggressive form of CAD and is more susceptible 
to death from CVD, mainly coronary events [29, 30], sug-
gesting that her lipid profile should be even more delete-
rious. These observations indicate the need of additional 
quantitative and/or qualitative laboratory procedures—
such as determinations of lipoproteins subfractions—to 
clarify some sex-related differences.
To date, there is paucity of data describing lipoprotein 
subfractions in postmenopausal diabetic women [1, 31, 
32]. It is unclear whether accurate analysis of subfrac-
tions of the several lipoproteins could be associated with 
improved identification of women at higher risk, before 
and after menopause, with or without DM. In addition, 
menopausal hormonal replacement therapy (HRT) may 
impose unique risk to women. We review and discuss 
the differences in cardiovascular risk and lipoprotein 
subfractions in pre- and postmenopausal women and in 
diabetic ones. Understanding sex-related differences in 
lipid metabolism, as well as the impact of menopause and 
DM in women, may contribute to improve cardiovascular 
risk assessment in women. The keywords postmenopau-
sal and menopause, lipoprotein, lipoprotein subclass and 
subfractions, type 2 diabetes, analysis, cardiovascular risk 
were selected for search in PubMed database, from 1980 
to 2017, in English and/or Portuguese language.
Cardiovascular risk in women
CAD and stroke have been the leading causes of death 
in both sexes accounting for 25.1% of the total mortal-
ity [33]. Even in the younger women, high mortality rates 
following myocardial infarction (MI) have been reported 
[34]. In recent years, improvements in hospital treat-
ment [4] have contributed to a 30% decrease in the num-
ber of women dying from cardiovascular events in USA 
[35] although these still cause more deaths than all other 
causes combined. Estimates of cardiovascular risk and 
clinical trials are commonly based on unbalanced sam-
ples and selection bias has limited gender comparisons 
of outcomes. Female sex is notably under-represented 
in clinical trials which frequently have a predominance 
of the men [36]. Also, there is evidence that women are 
undertreated and have cardiovascular risk factors less 
controlled compared to men [37], specially the diabetic 
population [38].
Apart from methodological concerns, atherogenesis 
per se could affect men and women distinctly. It is known 
that atherosclerosis involves inflammatory and throm-
botic processes. In premenopausal women, smaller lipid 
cores, less calcium, and fewer thin-capped atheromas 
were described, and estrogen-related anti-inflammatory 
effects on atherosclerotic plaques seem to contribute to 
their stabilization [39]. The plaque in women is shown 
to have less inflammatory components than in men 
which can implicate in slower development of vulner-
able plaques. Young women with acute coronary syn-
dromes often present plaque erosion, while men and 
older women frequently show the classical pattern of 
ruptured plaque followed by thrombosis [39]. In carotid 
arteries, lower atheroma burden and more stable plaques 
were described in women. Despite the ability of estrogen 
to stabilize the atheroma, prothrombotic effects of this 
hormone were reported. The reasons for sex-related dif-
ferences in the development and progression of athero-
sclerosis are not completely understood [39–42].
Several scores have been proposed for cardiovascular 
risk assessment and the Framingham risk score is one of 
the mostly used [43–46]. It has been recognized that the 
Framingham risk score underestimates risk in women 
since those with subclinical atherosclerosis are often 
classified as at low risk [47]. In an update of this score, it 
was proposed that women should be classified as ‘‘high 
risk’’, ‘‘at risk’’ and ‘‘at ideal cardiovascular health’’. High-
risk was defined by clinical evidence of CAD, peripheral 
artery disease and abdominal aortic aneurysm, or the 
presence of coronary risk equivalents, such as chronic 
kidney disease and DM, together with a 10-year predicted 
cardiovascular risk of ≥10%. At-risk women are those 
with at least one major risk factor [cigarette smoking, 
hypertension, dyslipidemia, obesity, poor diet, physical 
inactivity, family history of premature CVD, metabolic 
syndrome, evidence of advanced subclinical atheroscle-
rosis (coronary calcification, carotid plaque, or increased 
carotid intima-media thickness), poor exercise capacity 
on treadmill test and/or abnormal heart rate recovery 
after stopping exercise, systemic autoimmune collagen-
vascular disease (lupus or rheumatoid arthritis), history 
of preeclampsia, gestational diabetes, or pregnancy-
induced hypertension]. “Ideal cardiovascular health” was 
defined by adequate total cholesterol and blood pressure 
levels, fasting plasma glucose and body mass index, with 
heart-healthy behaviours including healthy diet, smoking 
abstinence and regular physical activity [47, 48].
CVD incidence in premenopausal women is signifi-
cantly lower than men at the same age (1 woman: 3–10 
men), but increases to an extent that the rate becomes 
similar at the age 65 years and higher by the age 75 years 
[49]. Among the epidemiological studies that examined 
Page 3 of 13Fonseca et al. Diabetol Metab Syndr  (2017) 9:22 
cardiovascular risk in women, the Nurses’ Health Study 
included one of the biggest sample [50]. This reported 
that 82% of coronary events could be attributed to the 
absence of a low-risk lifestyle. The INTERHEART study 
[6] revealed that nine risk factors accounted for 94% of 
the population attributable risk, including smoking, dys-
lipidemia, hypertension, DM, abdominal obesity, physi-
cal inactivity, low daily fruit and vegetable consumption, 
alcohol overconsumption, and a low psychosocial index 
(depression, locus of control, perceived stress, and life 
events). These are shown to be important risk factors for 
the development of CVD in both sexes.
In clinical settings, health care professionals commonly 
underestimate cardiovascular risk in women who are not 
as properly treated for CVD as men [47, 51]. Compar-
ing sexes after MI, in every age, women are more likely 
to have a history of hypertension; however, concerning 
other risk factors, sex differences exist only before the 
age of 55, when women were more likely to have medi-
cal insurance, history of DM, heart failure or stroke, 
and higher Killip class on hospital admission [4]. Clini-
cal symptoms of CAD also differ between sexes; men 
express classical symptoms such as angina, with pressure 
or squeezing to the chest, which can extend to the arms. 
Meanwhile, women tend to feel sharp, burning chest pain 
that can extend to neck, jaw, throat, abdomen or back 
and more frequently have atypical symptoms [52].
Sex differences could be raised concerning the efficacy 
of lipid lowering treatment. Statins have long been asso-
ciated with reductions in total cholesterol, LDL-c as well 
as some increase in HDL-c concentration. Several meta-
analyses reported significant reductions in cardiovascular 
outcomes with statins use for each 1 mmol/L decrease in 
plasma LDL-c [8, 9]. Accumulated evidence has consist-
ently shown that statins are equally effective in both sexes 
in the control of dyslipidemia and reduction of cardiovas-
cular morbidity and mortality [53, 54].
The deleterious impact of DM in cardiovascular mor-
bidity and mortality is greater in women compared to 
men. In 2011, DM was responsible for 281,000 deaths in 
men and 317,000 in women, the majority from cardio-
vascular causes [55]. Despite being a strong risk factor 
for both sexes, a greater impact in mortality from CAD 
is seen in women than in men [56]. Its presence almost 
eliminated the sex-related difference in cardiovascular 
morbidity and mortality, approximating the risk level of 
the diabetic woman to the non-diabetic men [57]. There-
fore, the diabetic woman needs special attention and 
optimized treatment of comorbidities to control risk fac-
tors and to decrease excessive cardiovascular mortality.
CVD is a major issue for women’s health most predom-
inantly at older age, although the younger women have 
a higher chance of fatality following coronary events. 
Despite lower absolute incidence compared to men, high 
mortality rates indicate the need to improve risk predic-
tion, early diagnosis and adequate treatment of risk fac-
tors and comorbidities to enhance women quality of life 
and survival. The increased mortality rates conferred by 
presence of DM are more prominent in the female sex. 
A careful analysis of these disparities between sexes is 
necessary.
Lipoprotein subfractions: determinations 
and potentialities
Routinely, lipoproteins have been determined accord-
ing to their molecular density (VLDL, LDL, and HDL) to 
assess cardiovascular risk. They have been classified by 
their size, charge, function, lipid core and apolipoprotein 
composition, and the resulting subgroups are called lipo-
protein subfractions [58, 59].
A considerable proportion of individuals that suffer 
from cardiovascular events shows either few or none of 
the traditional risk factors [58, 60]. The assessment of 
lipoprotein subfractions and apolipoproteins (apo) repre-
sents a way to improve the cardiovascular risk prediction; 
in addition, they may enhance the accuracy of atheroscle-
rosis detection, assist in treatment selection, and be use-
ful for counselling first-degree relatives of patients with 
atherosclerosis [61].
Numerous methods for lipoprotein subfractions deter-
mination have been described, mostly for research pur-
poses [61], such as analytic ultracentrifugation, vertical 
auto profile-II (VAP-II), density gradient ultracentrifu-
gation, gradient gel electrophoresis, nuclear magnetic 
resonance (NMR) spectroscopy, immunoaffinity chro-
matography, 2-dimensional gel electrophoresis and ion-
mobility analysis (Table  1). Heterogeneous techniques 
and nomenclature of lipoprotein subfractions limit data 
interpretation and study comparisons [59].
Analytic ultracentrifugation has been considered the 
gold standard of lipoprotein subclass analyses due to its 
precision and reproducibility, and used for validation of 
other techniques, but it is unfeasible for clinical practice 
[61]. This method is based on the lipoprotein ability to 
float when exposed to high gravitational forces. Accord-
ing to flotation rates, four LDL subfractions are grouped 
whose densities range from 1.025 to 1.060 g/mL [62].
The VAP-II uses a non-segmented continuous flow 
analyser for the enzymatic analysis of cholesterol in lipo-
protein classes, allowing a profile analysis with only 40 µL 
of plasma [63, 64]. Five subclasses for HDL, four for 
Lp(a), four for LDL, two for IDL and three for VLDL can 
be identified. The absorbance curve provides the density 
distribution of lipoprotein classes and subclasses in the 
centrifuge tube [65]. The procedures are simple and sen-
sitivity for the lipoprotein density classification is high. 
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However, some studies have shown low correlation of 
VAP with NMR and electrophoresis [66].
The gradient gel electrophoresis determines LDL 
and HDL size distribution directly from blood samples. 
According to major peaks size and percent distribution, 
seven LDL subclasses, from larger buoyant  LDL1,  LDL2a 
and  LDL2b to the smaller and less dense  LDL3a,  LDL3b, 
 LDL4a and  LDL4b can be detected [61]. Also, five HDL 
subclasses, ranging from small dense  HDL3c,  HDL3b, and 
 HDL3a to larger  HDL2a and  HDL2b, can be determined. 
This method does not provide concentrations but the 
size of predominant species or average size [67]. The 
two-dimensional gel electrophoresis improved the abil-
ity of the gradient gel electrophoresis in recognizing new 
HDL subfractions: α1, α2, and α3, with sizes of 11.2, 9.51, 
and 7.12 nm, respectively [68]. Its use has been limited to 
specialized labs [61].
Lipoproteins subfractions determination can also be 
based on size and charge using linear polyacrylamide gel. 
The technique is simple and fast but expensive [69, 70].
NMR spectroscopy allows quantification of lipopro-
tein subfractions given that each lipoprotein particle 
in plasma has its own characteristic lipid methyl signal. 
NMR uses a library of lipoprotein spectra reference in a 
linear least-square fitting computer program [71]. From 
the shape of the composite plasma methyl signal, the pro-
gram computes the subclass signal amplitudes. Particle 
sizes derive from the sum of the diameter of each sub-
class multiplied by its relative mass percentage [59, 61]. 
There is no need to physically separate the subfractions, 
which is a major advantage of the method. Lipoprotein 
subfractions identified are [71]:
  • for VLDL: large VLDL/chylomicrons, medium 
VLDL, small VLDL
  • for LDL, IDL, large LDL, medium small LDL, very 
small LDL
  • for HDL, large HDL, medium HDL, small HDL
Immunoaffinity chromatography and the ion-mobility 
have been used for research purposes. The former is able 
to isolate two HDL subfractions through their content of 
apolipoprotein A-I and apolipoprotein A-II [61], while 
the latter determines concentrations of lipoprotein sub-
fractions based on gas-phase differential electric mobility 
[59, 72].
The availability of several techniques and different 
parameters to express lipoprotein subfractions (concen-
trations, percent distribution of the HDL subclasses rela-
tive to the total or by average particle diameter) should 
explain part of the contrasting results on their association 
with CVD. The most consistent finding is the association 
of gradient gel electrophoresis-determined HDL subfrac-
tions [73]. The amount of large HDL identified by NMR 
has been correlated with the gradient gel electrophoresis 
 HDL2b results, but other NMR HDL components have 
shown weaker correlations [73].
Regarding LDL phenotype, substantial agreements 
among gradient gel electrophoresis, VAP, NMR, and ion-
mobility have been described [74]. Using any of these 
four methods, association of small, dense LDL with coro-
nary atherosclerosis progression was demonstrated [75]. 
Furthermore, gradient gel electrophoresis, NMR and 
ion-mobility confirmed that the associations were inde-
pendent of standard lipid measurements. A recent study 
on the comparison of ultracentrifugation, a novel electro-
phoretic method and two independent methods of NMR 
indicated ultracentrifugation as the most precise method 
for LDL particle determination with the lowest coef-
ficient of variation. The electrophoresis showed a close 
precision, whereas NMR showed the highest coefficient 
of variation [76].
Meanwhile, lipoproteins are heterogeneous even 
within each subclass and differ not only in size, charge 
Table 1 Summary of main advantages and disadvantages of methods for lipoprotein subfractions determination
References: [58–77]
Method Advantages Disadvantages
Analytic ultracentrifugation Precision and reproducibility Unfeasible for clinical practice, due to low availability high cost 
and time consuming
Vertical auto profile-II Simple procedures and high sensitivity Low correlation to NMR and electrophoresis
Gradient gel electrophoresis Determination of LDL and HDL size dis-
tribution directly from blood samples
Accuracy depends on correct standards and quality control
Provides only the size of predominant species or average size
Linear polyacrylamide gel Useful for clinical labs since it is simple 
and fast
High cost
Nuclear magnetic resonance spectroscopy No need of physically separation of the 
subfractions and fast procedure
Dependent of mathematical assumptions
Immunoaffinity chromatography/ion 
mobility
Ability to isolate two HDL subfractions Low availability and scarce data regarding efficiency
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and density, but also in their lipid and protein composi-
tion. Lipidomics and proteomics use mass spectrometry 
to identify and quantify lipid and protein content in a 
cell, tissue or organ, respectively [77–79]. These meth-
ods involve the use of complex technology in several 
research settings and may even help determine typical 
and abnormal lipoprotein composition [80, 81]. Changes 
in key components of lipoproteins under unusual cir-
cumstances, such as chronic inflammation and subclini-
cal atherosclerosis, cause their remodelling, affect their 
functionality and contribute to the atherosclerotic pro-
cess [82–84].
Evidence that certain lipoprotein subfractions enhance 
atherogenesis and increase cardiovascular risk empha-
sizes the importance of their determinations to improve 
the identification of those at higher risk [85, 86]. Deter-
mination methods differ by their basic principles, tech-
nology, complexity and accuracy. Such diversity limits to 
compare results and to assure the real contribution for 
the improvement in cardiovascular risk prediction.
Also, apolipoprotein determination has shown to 
improve cardiovascular risk assessment. Apo B100 con-
centration reflects the atherogenic lipoproteins (VLDL, 
IDL and LDL), while apo A-I has been considered a HDL 
surrogate. Apo B-to-apo A-I ratio provides a balance 
between the atherogenic and anti-atherogenic cholesterol 
particles and its usefulness as a predictor of cardiovascu-
lar events was demonstrated [87–89]. Lower apo B-to-
apo A-I ratio was reported in premenopausal compared 
to postmenopausal women and men [90]. Lipoprotein 
(a) has a similar structure to LDL, containing one apo-B 
molecule combined with an apo (a), known to diminish 
plasminogen activation and fibrin degradation, favour-
ing thrombosis. It has been considered an independent 
cardiovascular risk factor [91, 92]. There is no gender-
related differences in lipoprotein (a) concentration, and a 
predictive value was observed only in men [93].
Standardization and cost reduction will be necessary 
for lipoprotein subfractions and apolipoprotein determi-
nations reaching the clinical practice.
Lipid changes following menopause and hormonal 
replacement therapy
Women experience modifications on lipid profile and 
metabolism from child to adult life, during pregnancies 
and following menopause. Aging itself is associated with 
an increase in LDL-c, in part due to a reduction in its 
catabolism by the liver. However, the higher levels of total 
cholesterol, LDL-c and apo-B found after menopause 
compared to premenopausal ones are not completely 
explained by aging [94]. A cross-sectional analysis of the 
Framingham Offspring Study [14], including 1597 women 
and 1533 men, showed higher LDL-c concentration in 
male sex, as expected. Additionally, in the postmenopau-
sal compared to premenopausal women, increased LDL-c 
concentration was maintained after adjustments for age 
and several confounders.
Smaller denser Apo-B rich LDL particles are more fre-
quent in postmenopausal women, while larger and buoy-
ant LDL are decreased [16]. It is estimated that 14–30% 
of postmenopausal women have predominance of small 
dense LDL particles in contrast to only 5–7% in premen-
opausal counterpart [16, 95]. Lower HDL-c/total choles-
terol and apo-AI/apo-B ratios [16, 95], as well as direct 
association of small LDL-c particles with TG levels, and 
inverse associations of HDL-c and Apo-AI with Apo-B 
were reported following menopause [95]. Increased TG 
rich lipoproteins are associated with higher proportions 
of small dense LDL. In postmenopausal period, affinity 
to the hepatic LDL receptor is reduced in small dense 
LDL-c that is more susceptible to oxidation, transen-
dothelial transport and deposition in artery wall. This 
LDL subfraction has long been considered by the scien-
tific community as an independent risk factor for CVD, 
although this is still controversial as some studies have 
failed to determine this association after several adjust-
ments for confounding factors [58, 96–104]. Small dense 
LDL is also considered an independent risk factor for the 
development of type 2 DM [105], particularly in women 
[106]. Meanwhile, large HDL particles—also named 
 HDL2—play an essential role on reverse cholesterol 
transport and are considered cardioprotective [66, 85, 
107]. In postmenopausal women, the latter seemed to be 
diminished, with a predominance of cholesterol-depleted 
smaller HDL particles [18, 108–112]. These are not able 
to adequately transport cholesterol esters back to the 
liver, contributing to increased cholesterol concentra-
tions in the blood.
In men, low levels of  HDL2 particles (larger buoyant 
particles) have been associated with CAD indicating 
worse and diffuse lesions [113]. A cross-sectional analysis 
of more than 1000 women in UK showed that postmeno-
pausal ones tended to decrease their total HDL-c concen-
trations together with a decrease in  HDL2, without any 
difference in the  HDL3 concentrations when compared 
to the premenopausal women [18]. Similar reductions in 
 HDL2 were reported in high-risk postmenopausal women 
with untreated breast cancer [114]. Other studies have 
confirmed lower levels of large  HDL2 particles following 
menopause suggesting that  HDL2 concentrations might 
be influenced by the drop in female hormonal levels.
The role of sex hormones on lipid metabolism is sup-
ported by the demonstration that estrogenic therapy pre-
vents decrease in LDL-c and increases in TG and VLDL-c 
concentration after menopause. Mechanisms by which 
female hormones interfere on lipid metabolism have 
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been largely investigated. Estrogen is shown to increase 
both LDL receptor population in the liver, together 
with hepatic production of TG rich lipoproteins. Some 
authors have proposed that the lack of estrogen after 
menopause contributes to hypertriglyceridemia, low 
HDL-c and a predominance of small dense LDL particles, 
like the abnormalities seen in the metabolic syndrome 
[115]. This lipid profile is found in 15–25% of postmeno-
pausal women and might in part be responsible for their 
increased cardiovascular risk [115]. The very large lipid 
database (VLDL 10B) study [116], in which more than a 
million-people had their lipoprotein subfractions meas-
ured by density gradient ultracentrifugation, supported 
that, after middle age, women presented a shift towards a 
more atherogenic lipid profile.
These findings have raised questions about the util-
ity of hormonal replacement therapy (HRT) to prevent 
lipid metabolism abnormalities following menopause 
which could help in the prevention of CVD. Several 
clinical trials were conducted to investigate the effects 
of different schemes of HRT on the lipid profile after 
menopause [117–120], but those using accurate meth-
ods for the determination of subfractions of lipoproteins 
are less numerous [121, 122]. In one study, 38 postmeno-
pausal Brazilian women with formal indication for HRT 
were treated with continuous doses of 0.625 mg of con-
jugated equine estrogen (CEE) with (if they had uterus) 
or without 2.5 mg of medroxyprogesterone for 12 weeks. 
Lipoprotein subfractions were measured using an NMR 
spectroscopy at baseline and after treatment. Significant 
increases in larger VLDL and HDL particles, together 
with a decrease in the smaller HDL and VLDL particles 
were observed, but treatment did not induce significant 
differences in LDL subfractions [123].
Another trial evaluated the effect of estrogen alone 
or combined with medroxyprogesterone (1  mg of 
17β-estradiol and/or 0.625  mg of CEE) for 3  months in 
43 postmenopausal women [124]. Combined therapy 
resulted in a significant increase in the proportion of 
bigger HDL particles in circulation, also diminishing 
the absolute amount of smaller HDL particles. Other 
trials with estrogen alone in surgically induced meno-
pause have shown a tendency for an increase in HDL and 
 HDL2, but a variety of results were found for LDL parti-
cles [118–121]. Different HRT regimens, such as natural 
vs synthetic, transdermal vs oral, cyclic vs continuous, 
different progestogens or estrogens and doses have also 
been tested, but modifications in both lipid and lipopro-
tein subclasses are inconsistent across trials.
An interesting analysis of 243 postmenopausal women 
from the Healthy Women Study confirmed higher lev-
els of large HDL particles measured by NMR spectros-
copy between HRT users as compared to nonusers [125]. 
Despite lower levels of LDL-c, there were no differences 
in LDL subclasses or in coronary artery calcification 
(CAC) between the groups. As expected, having detect-
able CAC was associated with worse traditional lipid 
profile and increased atherogenic subfractions. Although 
an HRT-dependent shift on the proportions of lipopro-
tein subfractions could be expected in postmenopausal 
women, trials have not shown any benefit in cardiovas-
cular morbidity or mortality [126–128]. Only in a subset 
of younger women who initiated on HRT immediately 
after menopause some beneficial effects were detected 
[129]. Scientific societies have not recommended estro-
gen replacement aiming at treating dyslipidemia or 
reducing cardiovascular risk in postmenopausal women 
[130–132].
Since aging and menopause provoke lipid changes 
(decreased HDL, especially  HDL2, increased small dense 
LDL and TG) that elevate cardiovascular risk in women 
partially controlled by HRT, several open questions need 
to be addressed to improve the prognosis of the athero-
sclerotic disease.
Disturbances in lipid profile and lipoprotein subfractions 
in diabetes and in postmenopausal diabetic women
Type 2 DM commonly coexists with obesity and both 
are characterized by states of low-grade inflammation 
and insulin resistance. Type 1 macrophages accumu-
lated in the hypertrophic adipose tissue potentiate the 
pro-inflammatory cytokines secretion. Efflux of free fatty 
acids into circulation and the hepatic insulin resistance 
are responsible for the dyslipidemia in this condition 
[133, 134]. Molecular mechanisms of the lipid metabo-
lism disturbances in DM involve microRNAs, that are 
non-coding RNA molecules which regulate gene expres-
sion post-transcriptionally [135]. When microRNAs 
bind to their complementary sites at the 3′-untranslated 
regions of the target messenger RNAs (mRNAs) results 
in mRNA translational and repression or transcript 
degradation [136, 137]. They have been proven to play 
important role on insulin resistance and on the regula-
tion of liver metabolism affecting circulating lipids (miR-
122, miR-33a, miR-33b) and lipoprotein receptor. The 
relationship between insulin resistance and hypertriglyc-
eridemia has been recognized, whereas through micro-
RNA miR-34a, hypertriglyceridemia seems to favor the 
onset of DM [138, 139].
Obesity and impairment in glucose tolerance are 
frequent pathophysiological conditions that gener-
ate lipid-related cardiovascular risk in women follow-
ing menopause. As chronic inflammatory states, these 
conditions contribute to lipoprotein remodelling, com-
promising its function. Meanwhile, reduced estrogen 
levels contribute to a decrease in insulin sensitivity and 
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aggravate metabolic disturbances [140]. Therefore, post-
menopausal obese type 2 diabetic individuals are prone 
to a combination of disorders that markedly increases 
the risk of dying from cardiovascular events [141, 142]. 
Obesity-induced efflux of free fatty acids provokes 
insulin-mediated skeletal uptake of free fatty acids 
and increased liver exposure, which results in a rise in 
hepatic secretion of VLDL, together with a retarded 
clearance of VLDL and chylomicrons, contributing 
to hypertriglyceridemia. This pattern of large VLDL, 
named  VLDL1, results in increased precursors of small 
dense LDL-c [143].
The typical pattern of dyslipidemia in DM—charac-
terized by hypertriglyceridemia, low HDL-c and high 
small dense LDL-c levels—does not differ between sexes 
[144]. The HDL-c catabolism that occurs by the hepatic 
lipase and TG enrichment is elevated in conditions of 
insulin resistance [145]. Consequently, there is a reduc-
tion in HDL-c—that is predominantly from the  HDL2b 
subclass—as well as a relative or absolute increase in the 
smaller denser  HDL3b and  HDL3c [143]. Elevated non-
HDL-c and predominance of small dense LDL particles 
to large buoyant LDL, known as phenotype B [143, 146], 
raise atherogenicity even in near-normal limits of LDL-
c. As these particles are prone to oxidative modification, 
oxidized LDL is more frequently found in diabetic indi-
viduals, contributing to accelerate atherogenesis.
Small dense LDL particles have reduced affinity to LDL 
receptors and a prolonged plasma residence time, which 
could result in an increment in  LDL3a and  LDL3b and a 
decrement in  LDL1 and  LDL2a [143]. Of note, the oppo-
site and desirable profile, with higher concentration of 
large buoyant LDL, has been called phenotype A [143, 
146]. TG enrichment of these particles (VLDL and LDL) 
is due to the action of cholesteryl ester transfer protein 
(CETP), and hepatic lipase hydrolysis of TG and phos-
pholipids [143, 147].
In addition, abnormalities on scavenger receptor class 
BI (SR-BI), that promotes selective uptake of HDL cho-
lesteryl esters (HDL-CEs) into cells, have been described 
in the type 2 DM. An overexpression of SR-BI in the 
liver accompanied by a reduction of HDL-c levels were 
reported [148]. In contrast, genetic deletion of SR-BI 
resulted in increased HDL-c and atherosclerosis. These 
HDL-c molecules seemed to have an altered composi-
tion, including a shift toward large, buoyant HDL parti-
cles, and a significant increase in plasma apo A-I, but not 
apo A-II in HDL particle [149].
Consequences of insulin resistance can be present in 
individuals with the metabolic syndrome even before 
the clinical diagnosis of DM [143, 145]. Hypergly-
caemia and hypoadiponectinemia are involved in the 
pathophysiology of the diabetic dyslipidemia, but several 
questions remain unanswered [145].
Incidence of type 2 DM elevates after menopause 
[150] and that postmenopausal diabetic women are 
at increased cardiovascular risk compared to nondia-
betic women at the same age and hormonal status [30]. 
Such risk is strongly related to modifications in the lipid 
metabolism which are dependent of both, menopause per 
se as well as the diabetic condition. For our best knowl-
edge, the deleterious impact on lipid metabolism due to 
the presence of DM is similar in men and postmenopau-
sal women.
The increased risk for atherosclerosis in postmenopau-
sal diabetic women depends on low HDL-c levels, hyper-
triglyceridemia and predominance of small dense LDL 
particles [151]. Additionally, type 2 DM clusters with 
other disturbances from the spectrum of the metabolic 
syndrome, contributing to an elevated cardiovascular 
mortality [152]. Interestingly, the deleterious impact of 
DM in the LDL particle size seems to be greater in the 
diabetic women than in men [153, 154] and postmeno-
pausal diabetic women exhibited decreased large HDL 
particles  (HDL2) levels together with increased small 
HDL particles compared to normoglycemic women after 
menopause [31]. Figure  1 summarizes the main charac-
teristics of structural and functional abnormalities of 
lipid metabolism during atherogenic process and aging 
and the impact of diabetes mellitus.
Meanwhile, the hypothesis that estrogen therapy 
could alter lipids and improve cardiovascular risk pro-
file and outcomes has been tested in both, diabetic and 
non-diabetic women [123, 155–168]. Despite many stud-
ies that investigated the HRT effects on cardiovascular 
risk factors in postmenopausal diabetic women, just a 
few evaluated lipoprotein subfractions with conflicting 
results. Some authors described a significant increase in 
total HDL, predominantly on the  HDL2 subfraction, after 
intervention with combined HRT [168], while others 
failed to demonstrate any impact on HDL or LDL sub-
fractions [32, 166]. Due to the limited sample size and 
different HRT schemes used, studies available only gen-
erated hypothesis.
The effect of HRT on glucose homeostasis remains 
questionable [158]. A systematic review which included 
16 trials with 17,971 postmenopausal women with type 2 
DM demonstrated that estrogen replacement diminishes 
DM incidence and improves glycemic control [169], but 
there is no consensus yet.
To summarize, limited data on lipoprotein subfractions 
distribution in postmenopausal diabetic women, with 
or without dyslipidemia, are available. Different phar-
macological approaches to ovarian failure still deserve 
comparisons, as well as different analytical methods to 
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measure lipoprotein subfractions. Glycemic control level 
may add a confounding factor among comparisons con-
tributing partially for inconsistent results.
Worth of measurement of lipoprotein subfractions to the 
cardiovascular risk assessment in women
To date, there is insufficient evidence to recommend 
lipoprotein subfractions determination in clinical prac-
tice in both sexes at lower or higher cardiovascular risk 
[169]. Evidence that this measurement would impact on 
lipid-lowering treatment strategies is lacking either [170].
A small prospective nested case–control study in nor-
mal middle-aged women has previously demonstrated 
that baseline particle concentration was more predic-
tive of future cardiovascular events than LDL particle 
size [171]. On the other hand, an analysis of 286 post-
menopausal women from the Healthy Women Study 
confirmed an independent association of small dense 
LDL with higher CAC scores, suggesting a benefit from 
the addition of lipoprotein subfraction measurement for 
CVD prediction in this subset of individuals [172].
The largest prospective trial available included 27,673 
healthy women followed for 11  years [173]. Traditional 
lipid profile and NMR-determined lipoprotein subclass 
number and size were measured at baseline. No extra 
benefit on cardiovascular risk prediction with lipoprotein 
subfractions measurement after adjustment for non-lipid 
risk factors was obtained [173]. Finally, a recent system-
atic review of 24 studies, in which the impact of LDL par-
ticles for cardiovascular outcomes was examined in both 
sexes, reported similar findings [174].
In summary, controversies in this matter persist [175] 
and it is questionable whether determination of lipopro-
tein subfractions could be useful in clinical settings. Sev-
eral techniques for measurement are available, costs of 
the assays are high and the incremental benefit beyond 
traditional lipid measures may be minimal. Prospective 
studies demonstrating that advantages of lipoprotein 
subfractions to traditional lipid profile in the context of 
primary and secondary prevention of cardiovascular out-
comes are needed.
Final remarks
Despite the lower incidence of CVD in adult women com-
pared to men, their sex-related protective effect vanishes 
after menopause. This phase of women life per se imposes 
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Fig. 1 Main characteristics of structural and functional abnormalities of lipid metabolism during atherogenic process and aging and the impact of 
diabetes mellitus
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deterioration of their lipid profile and weight gain is a fre-
quent manifestation that could aggravate their predispo-
sition to metabolic disturbances. The cardiovascular risk 
scores and health care professionals commonly underesti-
mate their risk, and higher mortality and morbidity after cor-
onary events have been reported in women. Consequently, 
women are less properly treated for CVD than men.
The deleterious impact of type 2 DM in cardiovascu-
lar risk may be superior in women compared to men, 
emphasizing the importance of improving the risk assess-
ment, especially in postmenopausal diabetic women.
Since plasma lipoproteins constitute a major cardiovas-
cular risk factor, a deeper analysis of their subfractions 
might contribute to understanding why lipid-dependent 
cardiovascular risk in women is increased. A more ath-
erogenic lipid profile—hypertriglyceridemia, lower levels 
of both HDL-c and  HDL2, higher levels of both  HDL3 and 
small dense LDL—are usual after menopause, and modi-
fications in lipoprotein subfractions are also expected in 
the presence of hyperglycemia. Therefore, postmenopau-
sal diabetic women should be aggressively treated against 
dyslipidemia as well as against other risk factors.
Nowadays, no evidence supports that replacement of 
ovarian hormones has benefits in reducing cardiovascu-
lar events and mortality in different subgroups of women.
Finally, prospective trials including large samples of 
postmenopausal women, with or without DM, at differ-
ent treatments and metabolic control, should be con-
ducted to clarify whether lipoprotein subclass analysis 
would improve identification of higher-risk individuals. 
Considering that these determinations are expensive, 
cost-effectiveness studies are also necessary to address 
the worth of the addition of lipoprotein subfraction anal-
ysis in clinical practice.
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